PMVP:NASDAQ, PMV Pharmaceuticals, Inc.
PMVP stock overview
PMV Pharmaceuticals, Inc. (PMVP:NASDAQ) closed at $1.26 on November 6, 2026,
down 1.18% on the day.
The stock trades 34.0% below its 52-week high of $1.91
and 23.5% above its 52-week low of $1.02.
Over the past year, it lost 3.8%.
PMV Pharmaceuticals, Inc. is part of the Health Care sector.
Key figures
- Price
- $1.26
- Day change
- -1.18%
- Volume
- 194,299
- Average volume
- 672,903
- Market cap
- 95M+
- 52-week range
- $1.02 – $1.91
- 50-day average
- $1.39
- 200-day average
- $1.31
Price action over the past year
In 252 trading sessions since November 6, 2025, PMVP closed higher on 107 days (42%).
Its best day was February 27, 2026 (+24.09%) and its worst was October 26, 2026 (-11.02%).
The stock moved 10% or more in a single session 8 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
PMVP news
-
Nov 4, 2026:
Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026
-
Oct 12, 2026:
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
-
Oct 5, 2026:
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
-
Sep 17, 2026:
These Biotech Stocks Are Cheap Based On 1 Fundamental Measure
-
Sep 16, 2026:
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?
-
Sep 8, 2026:
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
-
Sep 1, 2026:
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
-
Sep 1, 2026:
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Similar stocks
Find more stocks like PMVP with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.